GLP-1 Drugs and MASH Fibrosis

GLP-1 based medicines are now part of the MASH discussion because trials have shown histologic improvement, meaning changes seen in liver-biopsy samples, not just lower liver-enzyme results. A September 2026 review describes mono, dual, and triple incretin agonists as promising options, especially when MASH occurs alongside obesity or type 2 diabetes. It also flags unresolved questions about tolerability, treatment duration, and why responses differ between people^[1].

MASH fibrosis is the part clinicians watch closely

MASH means metabolic dysfunction-associated steatohepatitis, a form of fatty liver disease with inflammation and liver-cell injury. Fibrosis is scar tissue that can accumulate as the liver is repeatedly injured. The recent review focuses on trials that used histology-assessed liver end points, which require biopsy evidence rather than relying only on imaging or blood tests^[1]. That distinction matters. A fall in weight or liver fat does not automatically prove that fibrosis has improved.

The most useful question is therefore not whether an incretin drug can produce weight loss. It is whether participants with established MASH and fibrosis show MASH resolution without fibrosis worsening, fibrosis improvement without MASH worsening, or both. Those are the biopsy-based outcomes reported in the major MASH trials discussed here^[2].

Semaglutide has phase 3 biopsy data

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a gut hormone that helps regulate insulin release and appetite. In the planned 72-week interim analysis of the phase 3 ESSENCE trial, researchers studied 800 people with biopsy-defined MASH and stage F2 or F3 fibrosis. MASH resolution without worsening fibrosis occurred in 62.9% of the semaglutide group and 34.3% of the placebo group^[2].

In that same interim analysis, a reduction of at least one fibrosis stage without worsening MASH was reported in 36.8% of participants assigned semaglutide and 22.4% assigned placebo. The combined outcome of MASH resolution and fibrosis reduction occurred in 32.7% and 16.1%, respectively^[2]. The signal is real. Still, this is an interim analysis from an ongoing 240-week trial, not a final answer about long-term clinical outcomes.

Dual agonism has a smaller, earlier trial

Tirzepatide activates both the GIP and GLP-1 receptors. GIP is another gut hormone involved in metabolic signalling. In a 52-week phase 2 trial, participants had biopsy-confirmed MASH with F2 or F3 fibrosis. Resolution of MASH without worsening fibrosis occurred in 44%, 56%, and 62% of the three tirzepatide groups, compared with 10% on placebo^[3].

For fibrosis improvement of at least one stage without worsening MASH, the reported proportions were 55%, 51%, and 51% across tirzepatide groups, versus 30% with placebo. Gastrointestinal events were the most common adverse events in the tirzepatide groups, and the trial authors said larger and longer trials are needed to assess efficacy and safety further^[3]. Readers looking for the drug background can see our tirzepatide guide.

Triple agonists are a research question, not a fibrosis result

Triple agonists add glucagon-receptor activity to GIP and GLP-1 activity. The 2026 review includes this class among emerging options for MASH-related fibrosis^[1]. But a well-known phase 2 retatrutide trial enrolled adults with obesity, not people selected for biopsy-defined MASH fibrosis. Its primary end point was percentage change in body weight at 24 weeks^[4]. Weight-loss data should not be relabelled as proof of fibrosis reversal.

At 48 weeks, retatrutide groups in that obesity trial had mean weight changes ranging from minus 8.7% to minus 24.2%, compared with minus 2.1% on placebo. Gastrointestinal adverse events were most common, and dose-dependent heart-rate increases peaked at week 24 before declining^[4]. That is useful background for the class, but it does not answer the liver-biopsy question. Our semaglutide guide explains the established GLP-1 drug in plain English.

What this is not

These trial findings do not mean every GLP-1 related medicine has been proven to reverse MASH fibrosis. The trials differ in drug, design, duration, patient population, and end points. They also do not establish which medicine is right for an individual person. MASH with fibrosis needs clinical assessment because fibrosis stage, other liver conditions, alcohol use, diabetes, and medication tolerability can all affect decisions^[1].

What we do not yet know

The review identifies treatment duration, tolerability, and variation in response as live questions for incretin-based treatment in MASH-related fibrosis^[1]. The ESSENCE report is also an interim analysis. The tirzepatide study was phase 2 and enrolled 190 randomized participants. Longer trials need to show whether biopsy improvements persist and whether they translate into fewer liver-related complications. That is a higher bar than a promising biopsy result.

Why this matters

The evidence has moved beyond the loose claim that weight-loss drugs might help the liver. Semaglutide and tirzepatide now have biopsy-based MASH trial results, while triple agonists remain an active research area rather than a demonstrated fibrosis treatment. If you are considering any medicine for liver disease, discuss the trial evidence and the limits of that evidence with a qualified clinician. For a broader class overview, see our GLP-1 receptor agonists explainer.